The rationale behind current drug trials aiming for LRRK2 inhibition in PD is principally based on this idea [42, 43] and also on a study reporting increased wild-type LRRK2 kinase activity in idiopathic PD [44]. This evidence concerns the gene LRRK2 and Parkinson disease.